In this issue of the Report, we have an exclusive interview with Alexandria (Sasha) Latypova, MBA, a former pharmaceutical executive, and independent analyst. Her prior reports on TrialSite News that deaths reported in VAERS after COVID-19 vaccination are not randomly distributed according to manufacturing lots as they are with influenza vaccines. Instead, they are aggregated in specific “hot lots.”
For example, from data on 33 lots of the Pfizer vaccine, 80% of the deaths have arisen from 35% of the lots. For Moderna, only 24% of the lots account for 80% of the deaths. Lot sizes were small initially, and some contaminated the metallic beads used in the manufacturing process. This explains reports and videos of injection site magnetism early in the campaign and why over time, these claims dissipated.
The lot sizes became larger, and the rushed nature of vaccine manufacturing invariable loads specific lots with more viable intact mRNA, while others have considerably less genetic material and or broken fragments of mRNA. Under the existing government contracts, there is no FDA or third-party inspection of the products for safety, quality, or purity. Because the US Department of Defense, under the Emergency Use Authorization countermeasures program, is the ”developer” of the vaccines, there is a complex array of biological defense contractors that make the components of the vaccines…